|View printer-friendly version|
|Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies|
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL –
– 50 Percent Complete Response Rate Observed in Patients with AITL –
– Rapid and Significant Reduction in Itching Among Patients with CTCL –
As of the
PTCL Cohort Data
CTCL Cohort Data
Cerdulatinib has demonstrated tolerability in both PTCL and CTCL. The most common grade 3 or greater adverse events across the PTCL and CTCL cohorts with a frequency > 5 percent were lipase increase (23 percent), amylase increase (18 percent), sepsis/bacteremia (8 percent), and neutropenia, pneumonia/lung infection and diarrhea (7 percent each). These events are manageable and further accrual is ongoing.
“The ongoing Phase 2a cerdulatinib data continue to demonstrate meaningful clinical activity, with particularly compelling complete response rates among AITL patients and the potential for durable response among patients with PTCL and CTCL,” said
“While still early, the continuing and durable response rates in PTCL and the encouraging responses in CTCL underscore the potential of cerdulatinib to control relapsed/refractory T-cell malignancies,” said
ASH Oral Session Details –
About Portola Pharmaceuticals, Inc.